Key statistics
As of last trade Innoviva Inc (HVE:MUN) traded at 19.71, -6.02% below its 52-week high of 20.98, set on Feb 26, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 19.71 |
|---|---|
| High | 19.71 |
| Low | 19.71 |
| Bid | 19.31 |
| Offer | 19.69 |
| Previous close | 20.00 |
| Average volume | 29.14 |
|---|---|
| Shares outstanding | 74.07m |
| Free float | 73.33m |
| P/E (TTM) | 7.42 |
| Market cap | 1.70bn USD |
| EPS (TTM) | 3.10 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 07:04 GMT.
More ▼
Press releases
- Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
- Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
- Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
